Myofibroblasts are associated with the progression of scirrhous gastric carcinoma

Fuyuhiro,Yuhiko; Yashiro,Masakazu; Noda,Satoru; Kashiwagi,Shinichiro; Matsuoka,Junko; Doi,Yosuke; Kato,Yukihiro; Muguruma,Kazuya; Sawada,Tetsuji; Hirakawa,Kosei

doi:10.3892/etm_00000086

Myofibroblasts are associated with the progression of scirrhous gastric carcinoma

Authors:
- Yuhiko Fuyuhiro
- Masakazu Yashiro
- Satoru Noda
- Shinichiro Kashiwagi
- Junko Matsuoka
- Yosuke Doi
- Yukihiro Kato
- Kazuya Muguruma
- Tetsuji Sawada
- Kosei Hirakawa
View Affiliations

Affiliations: Department of Surgical Oncology, Osaka City University Graduate School of Medicine, Osaka, Japan
Published online on: July 1, 2010 https://doi.org/10.3892/etm_00000086
Pages: 547-551

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Fibroblasts, particularly myofibroblasts, affect the malignant progression of cancer cells in vitro. However, to date few reports have addressed the clinical significance of myofibroblasts in the gastric cancer microenvironment. This study examined the correlation between myofibroblast expression and clinicopathological features in gastric carcinoma. A total of 265 primary gastric tumors resected by gastrectomy were stained with antibodies against α-smooth muscle actin and vimentin. Stromal cells positive for vimentin were considered to be fibroblasts. Myofibroblasts were defined as fibroblasts positive for α-smooth muscle staining. Myofibroblast-positive gastric carcinoma was established when myofibroblasts accounted for more than 25% of fibroblasts in the cancer stroma. Myofibroblast expression was positive in 92 (35%) of the 265 gastric carcinomas. Myofibroblast expression showed a significantly (p<0.001) high frequency in advanced gastric cancers (76 of 146), in comparison to the early stage cancers (16 of 119). Taken together, there was a statistically significant correlation between myofibroblast expression and scirrhous type gastric cancer (p<0.001), lymph node metastasis (p<0.001), lymphatic invasion (p<0.001) and peritoneal dissemination (p=0.005). The prognosis of patients with tumors positive for myofibroblast expression was significantly (p<0.001) worse, while a multivariate analysis revealed that myofibroblast expression was not an independent prognostic factor. These findings suggest that myofibroblasts are associated with scirrhous gastric cancer. Overexpression of myofibroblasts may therefore be a useful prognostic indicator of gastric carcinoma.

View Figures

View References

1.	Nakayama H, Enzan H, Miyazaki E and Toi M: Alpha smooth muscle actin-positive stromal cells in gastric carcinoma. J Clin Pathol. 55:741–744. 2002. View Article : Google Scholar : PubMed/NCBI
2.	Ronnov-Jessen L, Petersen OW, Koteliansky VE and Bissell MJ: The origin of the myofibroblasts in breast cancer. Recapitulation of tumor environment in culture unravels diversity and implicates converted fibroblasts and recruited smooth muscle cells. J Clin Invest. 95:859–873. 1995. View Article : Google Scholar
3.	Chauhan H, Abraham A, Phillips JR, Pringle JH, Walker RA and Jones JL: There is more than one kind of myofibroblast: analysis of CD34 expression in benign, in situ, and invasive breast lesions. J Clin Pathol. 56:271–276. 2003. View Article : Google Scholar : PubMed/NCBI
4.	Tuxhorn JA, McAlhany SJ, Dang TD, Ayala GE and Rowley DR: Stromal cells promote angiogenesis and growth of human prostate tumors in a differential reactive stroma (DRS) xenograft model. Cancer Res. 62:3298–3307. 2002.PubMed/NCBI
5.	Albini A and Sporn MB: The tumour microenvironment as a target for chemoprevention. Nat Rev Cancer. 7:139–147. 2007. View Article : Google Scholar : PubMed/NCBI
6.	Barth PJ and Westhoff CC: CD34⁺ fibrocytes: morphology, histogenesis and function. Curr Stem Cell Res Ther. 2:221–227. 2007.
7.	Eyden B: The myofibroblast: a study of normal, reactive and neoplastic tissues, with an emphasis on ultrastructure. J Submicrosc Cytol Pathol. 231–296. 2007.
8.	Eyden B: The myofibroblast: phenotypic characterization as a prerequisite to understanding its functions in translational medicine. J Cell Mol Med. 12:22–37. 2008. View Article : Google Scholar : PubMed/NCBI
9.	Orimo A, Gupta PB, Sgroi DC, et al: Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell. 121:335–348. 2005. View Article : Google Scholar
10.	De Wever O, Demetter P, Mareel M and Bracke M: Stromal myofibroblasts are drivers of invasive cancer growth. Int J Cancer. 123:2229–2238. 2008.PubMed/NCBI
11.	Tahara E: Growth factors and oncogenes in human gastrointestinal carcinomas. J Cancer Res Clin Oncol. 116:121–131. 1990. View Article : Google Scholar : PubMed/NCBI
12.	Yashiro M, Chung YS and Sowa M: Role of orthotopic fibroblasts in the development of scirrhous gastric carcinoma. Jpn J Cancer Res. 85:883–886. 1994. View Article : Google Scholar : PubMed/NCBI
13.	Japanese Gastric Cancer A. Japanese Classification of Gastric Carcinoma – 2nd English edition. Gastric Cancer. 1:10–24. 1998.
14.	Maruyama M, Sasaki T and Kubota H: [Endoscopic treatment of early cancer of the large bowel]. Gan No Rinsho. 32:1309–1316. 1986.
15.	Orimo A, Tomioka Y, Shimizu Y, et al: Cancer-associated myofibroblasts possess various factors to promote endometrial tumor progression. Clin Cancer Res. 7:3097–3105. 2001.PubMed/NCBI
16.	Nakazawa K, Yashiro M and Hirakawa K: Keratinocyte growth factor produced by gastric fibroblasts specifically stimulates proliferation of cancer cells from scirrhous gastric carcinoma. Cancer Res. 63:8848–8852. 2003.
17.	Inoue T, Chung YS, Yashiro M, et al: Transforming growth factor-beta and hepatocyte growth factor produced by gastric fibroblasts stimulate the invasiveness of scirrhous gastric cancer cells. Jpn J Cancer Res. 88:152–159. 1997. View Article : Google Scholar
18.	Tsujino T, Seshimo I, Yamamoto H, et al: Stromal myofibroblasts predict disease recurrence for colorectal cancer. Clin Cancer Res. 13:2082–2090. 2007. View Article : Google Scholar : PubMed/NCBI
19.	Wipff PJ, Rifkin DB, Meister JJ and Hinz B: Myofibroblast contraction activates latent TGF-beta1 from the extracellular matrix. J Cell Biol. 179:1311–1323. 2007. View Article : Google Scholar : PubMed/NCBI
20.	Ronnov-Jessen L and Petersen OW: Induction of alpha-smooth muscle actin by transforming growth factor-beta 1 in quiescent human breast gland fibroblasts. Implications for myofibroblast generation in breast neoplasia. Lab Invest. 68:696–707. 1993.
21.	Saito H, Tsujitani S, Oka S, et al: The expression of transforming growth factor-beta1 is significantly correlated with the expression of vascular endothelial growth factor and poor prognosis of patients with advanced gastric carcinoma. Cancer. 86:1455–1462. 1999. View Article : Google Scholar
22.	Kinugasa S, Abe S, Tachibana M, et al: Overexpression of transforming growth factor-beta1 in scirrhous carcinoma of the stomach correlates with decreased survival. Oncology. 55:582–587. 1998. View Article : Google Scholar : PubMed/NCBI
23.	Yoshida K, Yokozaki H, Niimoto M, Ito H, Ito M and Tahara E: Expression of TGF-beta and procollagen type I and type III in human gastric carcinomas. Int J Cancer. 44:394–398. 1989. View Article : Google Scholar : PubMed/NCBI